Clinical Updatesdisability progressionDisease-Modifying Therapy
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: Insights from the OPERA I and II Randomized Clinical Trials and Related Evidence
By MedXY|Oct 10, 2026
Continuous ocrelizumab treatment over 10 years in relapsing MS significantly delays disability progression, reduces relapse rates, and maintains a favorable safety profile, underscoring the clinical benefit of early high-efficacy therapy.